In 2018, Wang et al. noticed a significant downregulation of miR-144-3p in osteoporotic serum and bone tissue, altering osteoclastogenesis by targeting receptor activator of NF-κB (RANK); the authors suggest that this miRNA should be evaluated as a serum osteoporosis biomarker for therapeutic applications [51]. Here, TNFRSF11A is linked to osteoporosis.